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Abstract
Thrombin-activatable fibrinolysis inhibitor (TAFI) is a molecular link between
fibrinolysis and coagulation. TAFI gets activated either by thrombin, thrombinthrombomodulin complex, or plasmin. Once activated, TAFIa removes carboxyl-terminal
lysines from partially degraded fibrin, thus attenuating fibrinolysis. It has been previously
reported that heparin accelerates plasmin-mediated activation of TAFI and increases
thermal stability of TAFIa. In the present study we set out to identify heparin binding
sites on TAFI. We constructed TAFI variants that contained mutations in the regions
proposed to participate in the interaction with heparin. We identified several variants that
showed impaired binding to heparin. Of these, K211Q/K212Q, R320A/K324A and
K306A showed reduced acceleration by heparin of plasmin-mediated activation, and
K327A, K327A/R330A, and R320A/K324A showed reduced stabilization of TAFIa by
heparin. R320A/K324A bound very poorly to heparin, and hence might represent a useful
variant with which to study the importance of glycosaminoglycans in regulating TAFI
function.
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Chapter 1
Introduction

1.1 Haemostasis
Maintaining the balance between the processes of coagulation and fibrinolysis is
essential for proper haemostatic response. Once damage to a blood vessel occurs, a
haemostatic response is initiated that involves soluble plasma proteins, tissue
components, and receptors on platelets [1, 2]. This response is tightly regulated by the
opposing coagulation and fibrinolytic cascades (Figure 1-1). The coagulation cascade is
responsible for the formation of an insoluble fibrin clot at an injury site, while the
fibrinolytic cascade degrades the fibrin clot [1]. Any imbalances in the regulation of
these cascades can lead to excessive clot formation, which can lead to a heart attack or a
stroke, or inadequate clot formation, which can result in bleeding disorders such as
haemophilia [3]. If the two cascades are regulated properly, the haemostatic response is
localized to the site of the injury, due to the involvement of the above mentioned plasma
proteins, and cellular components.
The primary response to a vascular injury, which results in the exposure of blood
to subendothelial tissue, is initiated with the formation of a platelet plug. Inert platelets
circulate in close contact with the endothelium, but do not adhere to the endothelial cells
[4]. However, upon injury to the endothelium, platelets come into contact with
extracellular matrix components resulting in platelet activation and aggregation, leading
to the formation of a platelet plug [5]. Initially, the interaction of platelets with the
1

extracellular matrix is mediated through the platelet von Willerbrand Factor (vWF)
receptor Glycoprotein IB/V/IX [6] and collagen receptor Glycoprotein VI [7]. However,
this interaction alone is insufficient to allow adhesion and instead facilitates intracellular
signalling which activates integrins αIIb β3 and α2 β1 [7]. These integrins interact with the
extracellular matrix to facilitate firm adhesion of platelets to the wall of an injured vessel
resulting in the formation of a platelet monolayer. More platelets are rectuited to the
injury site by a variety of mediators that are synthesized once platelets adhere, and limited
activation of platelets takes place. These mediators are adenosine diphosphate (ADP),
adenosine triphosphate (ATP), thromboxane A2, and thrombin. Thrombin is produced on
the surface of activated platelets, while, ADP, ATP and thromboxane A2 are released
from activated platelets [5]. Upon activation platelets change morphology. Cytoskeletal
reorganization and secretion from storage granules takes place [8,9]. Among the secreted
granule components are calcium ions, which are released into the cytoplasm, as well as
vWF, and growth factors, which are released into the extracellular space. Another
morphological change that takes place once the platelets are activated is the exposure of
an ionic phospholipid, phosphatidylserine [9,10]. Phosphatidylserine provides a surface
for the assembly of the enzymes and cofactors of the coagulation cascade to form
functional complexes [9]. The secondary response to a vascular injury is the initiation of
the coagulation cascade. Tissue Factor (TF) is a transmembrane protein that is expressed
by various cells of the vascular wall, however, under normal conditions does not come
into contact with blood [11]. Upon a vascular injury, TF is exposed to flowing blood and
forms a complex with plasma protein factor VIIa (FVIIa). TF-FVIIa complex activates
circulating factors IX and X into IXa and Xa respectively [11].FXa and its activated
cofactor Va (FVa) form a complex on the activated platelet surface with the aid of the
2

aforementioned negatively charged exposed phospholipids. FXa-FVa complex on the
platelet surface is termed the ‘prothrombinase’ complex, as it activates prothrombin to
thrombin [12]. The majority of the circulating FV is activated by the thrombin that is
generated in the initial stages of the coagulation process. TF-dependant coagulation
pathway is often termed ‘extrinsic’ [2]. However, there is another pathway that can result
in the activation of prothrombin to thrombin. This pathway is termed ‘intrinsic’, and, in
vitro, can be initiated by the factor XII (FXII), high molecular weight kininogen, and
prekallikrein, which results in the activated FXII (FXIIa), which in turn activates FXI,
followed by activation of FIX [2]. However the current concept is that FXII, high
molecular weight kininogen, and prekallikrein do not play a role in the activation of the
intrinsic pathway in vivo but, rather, limited activation of FXI by thrombin initiates the
pathway through activation of FIX [13,14]. FIXa forms a complex with thrombinactivated FVIIIa that is termed the ‘tenase’ complex [2]. The function of this complex is
to convert FX to FXa. The assembly of the ‘tenase’ complex, just like the assembly of the
‘prothrombinase’ complex occurs on the negatively charged phospholipid surface of the
activated platelets [2]. The ‘extrinsic’ pathway is the main activator of the coagulation
cascade, while the ‘intrinsic’ pathway allows for amplification of the amount of thrombin
generated [15]. In addition to providing a negatively charged surface for the assembly of
the coagulation factors, activated platelets expose Glycoprotein IIb/IIIa receptors that can
efficiently bind the soluble plasma protein fibrinogen. Thrombin generated from both
‘extrinsic’ and ‘intrinsic ‘cascades cleaves platelet-bound fibrinogen to form fibrin to
further stabilize the platelet plug [16]. Thrombin then cleaves circulating fibrinogen to
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Figure 1-1. The balance between the coagulation and fibrinolytic cascades. The
extrinsic pathway of coagulation produces a small amount of thrombin that promotes
fibrin formation and the activation of the intrinsic pathway. The large amount of thrombin
produced by the intrinsic pathway consolidates the clot, in part through activation of
TAFI. In complex with thrombomodulin, thrombin no longer recognizes fibrinogen as a
substrate but its ability to activate protein C and TAFI is enhanced by three orders of
magnitude. Fibrin dissolution is accomplished by plasmin, which is formed by cleavage
of plasminogen by tPA with fibrin as an essential cofactor. Limited digestion of fibrin
leads to a form of fibrin that contains exposed carboxyl-terminal lysines. This form of
fibrin is a several-fold more effective cofactor for plasminogen activation. TAFIa
attenuates plasminogen activation by removing the carboxyl-terminal lysines, thereby
yielding a form of fibrin with no cofactor activity.

4

create a meshwork to form a fibrin plug over the aggregated platelets [17]. Furthermore,
generated thrombin activates FXIII, a transglutaminase, that cross-links fibrin monomers
to stabilize the fibrin clot [16].
Uncontrolled blood coagulation is dangerous, and is controlled by anticoagulant
pathways. The serine protease inhibitor (SERPIN) antithrombin (AT) downregulates clot
formation by inhibiting Factors Xa, XIa, and thrombin [18,19]. AT is much more efficient
at binding and inhibiting free circulating enzymes, then the enzymes that are assembled in
the ‘tenase’ or ‘prothrombinase’ complexes on the activated platelet surface [20] or fibrin,
in the case of thrombin [21]. The preferential affinity of AT to the free enzymes assists
with limiting the coagulation reactions to the sites of vascular injury. The inhibitory
function of AT is highly stimulated by heparin [22,23]. Because of this function, heparin
is used as anticoagulant therapy. The activated protein C pathway is another anticoagulant
pathway which controls coagulation. Activated protein C functions by inactivating the
glycoprotein cofactors FVIIIa, and FVa [24].
To maintain proper haemostasis once the healing to the injured vessel has
occurred, the fibrinolytic system is responsible for dissolution of the clot. Plasmin serves
as a central enzyme of the fibrinolytic cascade. Plasmin is a serine protease that cleaves
fibrin to form soluble fibrin degradation products (FDPs), which ultimately leads to the
dissolution of the clot. This protease is generated by the activation of plasminogen by
plasminogen activators, tissue-type plasminogen activator (tPA) and urokinase-type
plasminogen activator (uPA), with the former enzyme being more important to the lysis
of intravascular thrombi [25]. As in the case with coagulation, enzyme inhibitors play a
key role in controlling and localizing the fibrinolytic cascade. tPA and plasmin are bound
5

and inhibited by plasminogen activator inhibitor (PAI-1) and α-antiplasmin respectively
[26,27]. Plasmin promotes activation of plasminogen to form more plasmin by cleaving
fibrin to expose carboxyl-terminal lysines [28,29]. This partially degraded form of fibrin
possesses exposed carboxyl-terminal lysine residues and acts as a more efficient cofactor
for tPA-mediated activation of plasminogen, by providing binding sites for both
plasminogen and tPA [25]. Additional roles of the carboxyl-terminal lysines will be
discussed below.
Studies in the 1990’s defined a molecular mechanism that functionally links the
coagulation and fibrinolytic cascades. Studies of clot lysis in vitro revealed the presence
of a factor that was activated by the coagulation cascades and appeared to inhibit the
fibrinolysis; accordingly, activation of protein C in the clots prevented the action of this
factor. The factor was purified and found to be procarboxypeptidase B-related zymogen,
and was termed thrombin activatable fibrinolysis inhibitor (TAFI) [30,31]. TAFI
attenuates fibrinolysis by cleaving C-terminal lysine residues from partially degraded
fibrin, yielding a form of fibrin that does not possess cofactor activity for tPA-mediated
plasminogen activation [32,33].

1.2 TAFI
Thrombin-Activatable fibrinolysis Inhibitor (TAFI) is a 60-kDa procarboxypeptidase Brelated glycoprotein zymogen that was originally thought to be expressed only in the
liver, and secreted to circulate in the plasma [34]. However, recent studies have shown
that TAFI is expressed, although in smaller amounts, in megakaryocytes, endothelial
6

cells, macrophages, and adipocytes [35-37]. The translated product consists of 423 amino
acids, of which 22 make up a signal peptide, 92 amino acids make up an activation
peptide, while the remaining 309-amino acids represent a catalytic domain. The signal
peptide is cleaved before secretion from the liver [34].The theoretical molecular weight of
TAFI zymogen is approximately 46 kDa, however, the apparent molecular weight of
TAFI on SDS-PAGE is 60 kDa, due to N-linked glycosalation of TAFI [38,39]. TAFI
zymogen is inactive and consists of the activation peptide, and the catalytic domain.
TAFI becomes activated upon the cleavage at Arg92 which results in release of the
activation peptide, and exposure of the TAFIa active site [31,40] .Proteolysis of the
activation peptide is catalyzed by thrombin, or plasmin (Figure 1-2) [34]. However, both
activators are relatively inefficient in cleaving the activation peptide. Thrombin, in
complex with the endothelial cell surface cofactor thrombomodulin (TM), is 1250-fold
more effective at activating TAFI [41]. In similar fashion, plasmin, in the presence of
glycosaminoglycans, such as heparin, exhibits a 16-fold increase in the activation
efficiency [43]. Previously, it has been suggested that thrombin-TM complex is the
physiological activator of TAFI, due to the apparent efficiency in activating TAFI
compared to thrombin. In comparison to plasmin, even in the presence of
glycosaminoglycans, thrombin-TM complex exhibits 10-fold greater catalytic efficiency
[43]. However, it has been shown that half-maximal effect of TAFIa on inhibition of clot
lysis time is achieved at 1nM in vitro [41]. This represents less than 2% of the total
concentration of TAFI in plasma. Therefore, significant inhibition of fibrinolysis can be
achieved via activation of TAFI by thrombin, or plasmin alone, and this has certainly
been demonstrated both in vitro and in vivo in animal models [44,45,46,47]. It is
important to note that the contribution of these individual activators is unknown; in fact,
7

the contribution of these activators may be dependent on the location of the activation of
TAFI, as well as the presence of vascular injury [43].
Vascular injury exposes glycosaminoglycans that are present in the extracellular matrix
[48]. Therefore, plasmin-mediated activation of TAFI may be a significant contributor to
proper clot stability at the injury site. On the other hand, if the vessel is not injured,
thrombin-TM may play a key role in activation of TAFI, and proper fibrinolysis control
[43,44].
To date, there are no known endogenous inhibitors of TAFIa. However, it has been
shown that the intrinsic thermal instability is responsible for the inactivation of the
enzyme; the activity of TAFIa appears to spontaneously decay with a half-life of 8-15
minutes [49,55]. This phenomenon has been associated with a marked structural change
in the enzyme as assessed by measurement of the intrinsic fluorescence [50]. Crystal
structures of TAFI have shed some light on the structural basis for the intrinsic instability
of this enzyme. Crystal structure analysis suggests that residues 296-350 of TAFI play a
key role in the thermal stability. Before cleavage at Arg92, the activation peptide of TAFI
stabilizes the above mentioned region. Once cleavage occurs, the activation peptide no
longer interacts with this region. This is followed by increase in the dynamics of this
region and unfolding of TAFIa, yielding exposed thrombin and plasmin cleavage sites of
TAFIa [51,52,53]. Proteolytic cleavage of activated TAFI by thrombin, or plasmin has
also been suggested to play a critical role in regulating levels of TAFIa, since this
cleavage yields a form of TAFIa that is inactive. Thrombin cleaves TAFIa at Arg302,
while plasmin cleaves TAFIa at Arg302, Lys327, and Arg330 [49,53]. (Figure 1-2)
However, it has been shown that this proteolytic cleavage by thrombin can occur only
after thermal inactivation of TAFIa, while cleavage of TAFIa by plasmin can occur
8

before and after thermal inactivation. Proteolytic cleavage of TAFIa by plasmin is
accelerated following thermal inactivation. This suggests that thermal inactivation is a
primary method of regulating TAFIa levels [49,53] ; indeed, mutants of TAFI, both
naturally occurring and those created in the 296-350 region, that alter the intrinsic
stability of TAFIa, correspondingly alter the antifibrinolytic potential of the enzyme
[54,55]. The importance of proteolytic cleavage of TAFIa, as a way of regulating TAFIa
levels, remains unknown [49,53]. In vitro clot lysis studies have shown that TAFIa
exhibits the antifibrinolytic effect in a threshold-dependant manner. Like every threshold
system, this one is also very complex, as the threshold concentration of TAFIa is
dependent on the concentrations of other components of the pathways, such as
plasminogen, plasminogen activator, and antiplasmin. However, as long as TAFIa
concentration remains above a certain level, fibrinolysis is attenuated [56]. However, due
to its intrinsic instability, and the consequential short half-life, the concentration of TAFIa
gets progressively lower, and falls below the threshold value. Therefore increased clot
lysis time is highly dependent on the half-life of an enzyme, which dictates the
concentration of TAFIa [56, 57], as a more stable variant of TAFI (Ile325) exhibits
increased antifibrinolytic potential [58].

9

Figure 1-2. Activation of TAFI and inactivation TAFIa. TAFI consists of a prodomain (black), which contains four N-linked glycans, and a catalytic domain (grey).
Cleavage at Arg92 releases the activation peptide and formation of TAFIa. TAFIa is
thermally unstable, and undergoes a conformational change which is associated with loss
of carboxypeptidase B activity and formations of TAFIai. This conformational change
also exposes Arg302, Lys327 and Arg330.The figure was adapted and modified from
ref.41. The inset shows the location of Arg92, the target of thrombin and plasmin
cleavage. Crystallographic data are from ref. 39 (PDB # 3D66). The side chain of the P1
arginine recognized by thrombin and plasmin is shown in red. The side chains of residues
putatively involved in pinning Arg92 to the side of the zymogen are shown in cyan.
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Although there are no known endogenous inhibitors of TAFIa, the role that
several reversible inhibitors have on fibrinolytic effect of TAFIa has been studied [58].
Two of these inhibitors are 2-guanidinoethylmercaptosussinate (GEMSA), and potato
tuber carboxypeptidase inhibitor (PTCI). It was found that these inhibitors of TAFIa
exhibit a biphasic effect on the antifibrinolytic potential of TAFIa. This biphasic effect
was found to be concentration dependant, where the clot lysis was prolonged at lower
concentrations of the inhibitor, while enhancing clot lysis at higher concentrations of the
inhibitor. This effect is thought to be due to the dynamic equilibrium of TAFIa bound to
the inhibitor, and free TAFIa. When TAFIa is not bound to the inhibitor, it displays
carboxypeptidase activity [58]. However, at body temperature, it undergoes spontaneous
thermal inactivation rapidly [49]. On the other hand, TAFIa that is bound to the inhibitor
does not display carboxypeptidase activity, but the half-life of TAFIa is increased when it
is bound to the reversible inhibitor [40]. Since there is a dynamic equilibrium between
bound and unbound TAFIa, as unbound TAFIa becomes inactivated, the dynamic
equilibrium shifts to replenish the pool of unbound TAFIa as the reversible inhibitor is
released. This observation would only remain true when the concentration of the
reversible inhibitor is low enough, or the concentration of TAFIa is high enough, to
sustain a pool of TAFIa that is not bound to the inhibitor. Since it has been shown that
thermal stability plays a great role in the antifibrinolytic activity, extension of the half-life
of TAFIa, and therefore clot-lysis time via reversible inhibitors can be used
therapeutically [58]. However, since the biphasic effect is greatly dependant on the
concentrations of TAFIa and the inhibitor in question, the effect that various
concentrations of the inhibitor have on each individual becomes more complicated.
Therefore, the use of these reversible inhibitors as therapeutic agents may be problematic
9

[58]. A number of studies on have been done to evaluate whether administration of the
reversible TAFIa inhibitor alone improves endogenous thrombolysis. However, to date, in
vivo results for various synthetic and naturally occurring inhibitors have been
contradictory, as the efficiency of the inhibitor was found to be dependent on a number of
factors, such as: the type of the thrombosis model, the studied animal species, the type of
inhibitor, and whether the administration of the inhibitor is before or after the thrombus
formation [59]. Although the reason for such great variability in data is unknown, there is
a possibility that the biphasic effect of TAFIa inhibitors may contribute to that variability.
One of the TAFIa inhibitors, AZD9684 was administered to pulmonary embolism
patients in a phase II study [59]. However, according to the report by Astra Zeneca, the
company that was developing this inhibitor, it is now discontinued (60).
As mentioned above, plasmin is a central enzyme of the fibrinolytic cascade.
Plasmin digests fibrin, which structures a fibrin clot, into soluble FDPs. This results in the
dissolution of a fibrin clot [25,59]. Fibrin provides binding sites for t-PA and
plasminogen, and thus accelerates activation of plasminogen by 500-fold. The formation
of this complex also restricts the activation of plasminogen to the site of a fibrin clot [62].
Initial plasmin cleavage of fibrin, however, cleaves fibrin to yield fibrin with exposed Cterminal lysines. These lysines bind t-PA and plasminogen, yielding a form of fibrin that
acts as a better cofactor for t-PA-mediated plasminogen activation. In fact the increased
efficiency of the partially degraded fibrin as a cofactor for plasminogen activation is
approximately 3-fold [32,63]. It should also be noted that plasmin can cleave
plasminogen from the initial Glu-plasminogen form to Lys-plasminogen form, which is
more readily activated by t-PA to form Lys-plasmin [62,64]. Once activated, TAFI
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exhibits carboxypeptidase activity on the partially degraded fibrin, which possesses
carboxyl-terminal lysines, by cleaving these residues from the partially degraded fibrin.
TAFIa attenuates fibrinolysis through a number of mechanism, however, all based on its
ability to cleave carboxyl-terminal lysines from partially degraded fibrin. As mentioned
above, partially degraded fibrin exhibits greater cofactor activity for tPA-mediated
plasminogen activation. TAFIa thus reduces the cofactor activity of the partially degraded
fibrin, and therefore attenuates fibrinolysis [32]. In the same manner, TAFIa reduces the
conversion of Glu-plasminogen to Lys-plasminogen by removing carboxyl-terminal
lysine residues from partially-degraded fibrin, which also downregulates fibrinolysis [32].
Both downregulation mechanisms result in lower plasminogen activation, and therefore
lower plasmin concentration. As mentioned previously, one of the inhibitors that
regulates fibrinolysis is α2-antiplasmin, which binds plasmin irreversibly, and therefore
inhibits the function of plasmin [27]. Plasmin, however, has the ability to bind to the
lysine residues of the partially degraded fibrin. When bound to fibrin, plasmin is
protected from the inhibition by α2-antiplasmin [65]. Once TAFIa cleaves the carboxylterminal lysines from partially degraded fibrin, plasmin can no longer bind to the fibrin,
and therefore is more readily inhibited by α2-antiplasmin [66]. This results in lower
localized plasmin concentration, which in turn corresponds to attenuation of clot lysis.

1.3 Plasmin
As previously mentioned, plasmin is a central enzyme of the fibrinolytic cascade,
which is produced via activation of the proenzyme plasminogen. Plasmin is a serine
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protease that cleaves fibrin to form fibrin degradation products, which ultimately leads to
the dissolution of the clot [67-69]. Plasminogen is a single-chain glycoprotein that
circulates in plasma at an approximate concentration of 2 µM. Plasminogen activation to
plasmin occurs through cleavage of Arg561-Val562 by tPA or uPA [69-71]. Plasmin is a
two-chain serine protease, linked by disulfide bonds, with an approximate molecular
weight 85 kDa, the heavy chain and light chain being 60 kDa and 25 kDa respectively.
The heavy chain of plasmin is composed of five kringle domains, which are involved in
the interaction of plasmin with other proteins, including fibrin, and the inhibitor of
plasmin, α2-antiplasmin [69]. Although plasminogen activation is possible without being
bound to fibrin, once tPA and plasminogen are both bound to partially degraded fibrin,
via carboxyl-terminal lysines, plasminogen activation is greatly accelerated. The
carboxyl-terminal lysines are removed by TAFIa, thus reducing plasminogen activation,
and reducing plasmin concentration [69, 25]. Although plasmin is considered to be the
main enzyme of the fibrinolytic cascade, it can also act as an antifibrinolytic enzyme,
through activation of TAFI [34]. Plasmin activates TAFI to form TAFIa, which
ultimately attenuates fibrinolysis [32]. It has been reported that plasmin substrate
specificity has been subjected to negative selection during evolution to prevent autoactivation of plasminogen by plasmin. Plasmin is a very poor activator of plasminogen,
which is important to prevent short-circuiting of the fibrinolytic system through autoactivation of plasminogen by plasmin. Optimal substrate for catalysis by plasmin contain
a lysine or an arginine residue at the P1 position, an aromatic residue at the P2 position,
either arginine, lysine, or serine at the P1’ position, as well as arginine, lysine, or glycine
at the P2’ position. Plasmin does not have stringent specificity at the P3 position of the
substrates [72]. Plasminogen, however has a proline at the P2 position which prevents
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cleavage by plasmin [73]. Of note, TAFI has a proline at the P2 position as well, Pro91,
which may account for the relatively inefficient activation of TAFI by plasmin
[74].Therefore, plasmin’s role in fibrinolysis is dependent on the balance between
activation of plasminogen, inhibition of plasmin by antiplasmin, and plasmin-mediated
activation of TAFI [32,65].

1.4 Multifunctional Role of Glycosaminoglycans
Glycosaminoglycans play a central role in regulating the balance between
coagulation and fibrinolysis. Heparin is a glycosaminoglycan that is synthesized in mast
cells and consists of alternating 14 linked residues of D-glucuronic acid and Dglucosamine [75]. During its biosynthesis, heparin chains are attached to a core protein,
serglycin, through serine residues. However, this peptidoglycan gets cleaved by βendoglucoronidase to yield a number of heparin molecules [76]. Another molecule that is
structurally related to heparin is heparan sulphate, which also contains repeating of Dglucuronic acid and D-glucosamine residues. Compared to heparin, however, heparan
sulfate is less sulfonated. On average, heparin contains 2.7 sulfate groups per
disaccharide, while heparan sulfate, contains one sulfate group per disaccharide [77].
Unlike heparin, heparan sulfate gets synthesized by most mammalian cells, and becomes
incorporated into the cell surface and the extracellular matrix [78]. The molecular weight
of heparin varies from 5kDa to 40 kDa, while the molecular weight of heparan sulphate
varies between 5kDa to 50 kDa [77]. Due to its heterogeneity, heparin, as well as other
glycosaminoglycans, can bind to a variety of proteins and therefore play an important role
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in the biological function of these proteins [75,79]. The specificity of the interactions of
glycosaminoglycans and the binding protein in question depends on the ionic interactions
of the negatively charged sulphate with positively charged basic residues. However, it has
also been shown that hydrogen bonds may play a role in heparin binding to proteins.
Arginine residues exhibit tighter binding to heparin than lysine residues. This
phenomenon is largely attributed to the stronger hydrogen bond between the guanidine
side chain of arginine and the sulphate group of heparin, compared to the ammonium side
chain of lysine [80].
Heparin accelerates inhibition of a number of proteinases of the blood coagulation
system by proteinase inhibitors antithrombin and heparin cofactor II. Antithrombin
inhibits thrombin, as well as Factors IXa, and Xa, while heparin cofactor II inhibits
thrombin only [22, 23]. It has been previously reported that heparin first binds to the
inhibitor, either antithrombin or heparin cofactor II, forming a complex. The formation of
this complex induces a conformational change, which yields a more rapid reaction of the
inhibitor and the proteinase in question. Heparin accelerates inhibition of thrombin by
antithrombin by a factor of 2000 [81,22]. However, there is a minimum length
requirement for heparin to bind to certain proteins, and therefore exhibit its effect on
inhibition. In the case of thrombin inhibition by antithrombin, heparin that is made up of
at least 5 saccharide units, with a 3-O-sulfo group on an internal glucosamine residue, is
specifically required for high affinity to antithrombin [82]. However, this pentasaccharide
is a minimal requirement for binding. There is also a minimal length requirement, of at
least 16 saccharides, needed to accelerate the inhibition of thrombin by antithrombin [83].
This requirement is not uniform for inhibition of other proteins by antithrombin, heparin
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that is as small as a pentasaccharide is able to bind antithrombin and catalyze the
inhibition of factor Xa [84]. This is the basis for the synthetic heparin-like anticoagulant
drug Fondaparinux, that specifically stimulates inhibition of FXa by antithrombin. This
specificity is thought to underlie the reduced bleeding complications that are a feature of
Fondaparinux compared to unfractionated heparin or low molecular weight heparin [85].
In a similar fashion, the protein also has to have a specific sequence motif to
facilitate heparin binding. Through analysis of a number of heparin binding proteins,
initially two heparin binding consensus sequences were proposed: XBBXBX and
XBBBXXBX, where B is a basic residue and X is a hydrophobic residue. It is suggested
that if the XBBXBX sequence is in a β-strand conformation, or the XBBBXXBX
sequence is folded into an α-helix, lysine and arginine residues would be exposed, while
hydrophobic residues would be pointing into the protein core [86]. However, a third
heparin binding consensus sequence has been proposed, XBBBXXBBBXXBBX, which
is found in vWF [87]. Although consensus sequence is a valuable tool in screening for
potential heparin binding sites, many heparin binding proteins do not contain these
specific sequences. Folding of the protein may be the determining factor in heparin
binding, as it can bring distant basic residues into close proximity and thus facilitate
heparin binding [77]. It was also found that, regardless of the tertiary structure, a distance
of 20 Å between basic residues was able to facilitate heparin binding [88].
Heparin has been used as an anticoagulant therapeutic agent for deep venous
thrombosis in clinical settings since the 1930s. One of the main uses of heparin is to
prevent thrombus growth and pulmonary embolism, though accelerated inhibition of the
proteases involved in the coagulation cascade. Unfractionated heparin is administered
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intravenously as a treatment for venous thrombosis. However, due to variable individual
responses to unfractionated heparin, appropriate dosage has been one of the problems
associated with this therapy [89,90]. Another problem associated with heparin therapy is
heparin-induced thrombocytopenia (HIT). Several types of HIT have been defined.
However, only one type is associated with an increased risk of thrombosis. This type of
HIT is induced by an immune response. Platelet Factor 4 (PF4) is a molecule that gets
released from platelet granules upon activation of platelets. PF4 is a positively charged
molecule that binds to the negatively charged heparin molecule. Patients that are
diagnosed with this type of HIT produce an IgG antibody against the PF4-heparin
complex. This antibody has the ability to bind to platelets through an Fc receptor and
induce activation of platelets, followed by activation of coagulation, and thrombus
formation. This type of HIT is also associated with the decrease of platelets, as antibodycoated platelets get cleared by phagocytic cells [91]. Therapeutically introduced heparin,
as well as endogenous heparin gets cleared from the body. It has been previously reported
that liver sinusoidal endothelial cells of the lymph nodes, liver, and spleen are the
principal site of clearance of heparin from the vascular and lymphatic circulation [92].
These cells express a hyaluronic acid receptor (HARE), also known as Stabilin-2, an
endocytic receptor that is responsible for binding, internalizing, and degradation of
heparin [93].
Interaction of heparin with antithrombin and heparin cofactor II is the basis of its
anticoagulant activity. However, heparin also binds to TAFI, leading to increased
activation of TAFI by plasmin, as well as increased stability of TAFIa [43]. Several forms
of heparin-like glycosaminoglycans tested, such as heparan sulfate, low molecular weight
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heparin, chondroitin sulfate, keratan sulfate, and dextran sulfate, have a similar effect on
TAFIa activation by plasmin [43]. Like heparan sulfate, chondroitin sulfate and keratan
sulfate are expressed by various mammalian cells [94]. Low molecular weight heparin is
a derivative of the unfractionated heparin [95], while dextran sulfate is synthetic analogue
of heparin [96]. Chondroitin sulfate contains the same major disaccharide repeat as
heparin and heparan sulfate, D-glucuronic acid and D-glucosamine, while keratan sulfate
contains a disaccharide repeat of D-galactose and D glucosamine [94]. Since TAFIa
attenuates fibrinolysis, heparin may now act as an antifibrinolytic molecule. Little is
known about this function of heparin, as it was recently discovered. However, this may be
an important aspect to consider when heparin is administered as an anticoagulant drug.

1.5 Potential TAFI-Heparin Interactions
Glycosaminoglycans, such as heparin, have been reported to accelerate activation
of TAFI by plasmin and increase the half-life life of TAFIa [43]. However, the binding
sites of heparin on TAFI are still unknown. Several reports of the crystal structure of
TAFI, in the presence of sulfate ions, have shed some light on the potential interaction
sites of TAFI and glycosaminoglycans (Figure 1-3) [50,51]. Mao and coworkers have
reported that, based on the sequence analysis, Trp210-Ser221 is a potential binding site.
This region possesses sequence similarity to that of other glycosaminoglycan binding
proteins [43]. However, according to the crystal structure of bovine TAFI, in the presence
of sulfate ions, only one out twenty two sulfate molecules was bound to that region of
TAFI. The rest of the sulfate molecules were bound to the pro-domain region, the region
from the instability region to the active site cleft, as well as the instability region.
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However, it should be noted, that binding of heparin in the segment spanning between the
instability region and the active site cleft would actually hinder the substrate binding and
therefore interfere with the carboxypeptidase activity of TAFI. While binding of heparin
in the pro-domain may be important for various biological activities of TAFI, it would not
explain the increased stability of TAFIa. Binding of heparin to the instability region of
TAFI would explain the increased half-life of TAFIa in the presence of heparin [51].
Since therapeutic manipulation of TAFI function by heparin is a potentially important
goal, and since clinically used heparins and heparin analogues may be compromised by
their effect on the balance between coagulation and fibrinolysis through modulation of
TAFI, we undertook this study to define heparin binding sites on TAFI.
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Figure 1-3. Potential glycosaminoglycan binding sites on TAFI. The ribbon
representation of bovine TAFI (taken from ref. 50) is on the left. Bound sulfates, which
represent potential glycosaminoglycan binding sites are clustered in three regions: at the
activation peptide (blue sulfates), at the dynamic region (orange sulfates), and within the
active site cleft (purple sulfates). Glycosaminoglycan binding to the active site would
most likely hinder enzymatic activity of TAFIa, therefore it is unlikely to be a site of
heparin binding. The ribbon representation on the right was prepared from the
crystallographic data PDB #3D66 (Marx, 2008). A putative glycosaminoglycan-binding
site spanning Trp210-Met215, contains –XBBXBX- motif where X represents hydrophobic
residues (green side chains) and B represents basic residues (blue side chains). Also
shown is the position of Arg92, which is the site of TAFI cleavage by thrombin or
plasmin.
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1.6 Overall Hypothesis and Specific Objectives
The overall goal of this study is to begin to understand the interactions between
heparin and TAFI, and the resulting biological effects of these interactions in terms of
plasmin-mediated activation of TAFI and thermal stability of TAFIa. It has been
previously reported that the presence of heparin increases plasmin-mediated TAFI
activation and TAFIa stability. However, the interactions that are responsible for these
effects remain unknown. By mutating basic residues in the potential heparin binding sites,
we will attempt to determine if these residues participate in heparin binding. Hence these
TAFI variants will be used to study the overall hypothesis that the residues that
potentially participate in heparin binding are responsible for either increased TAFI
activation by plasmin or increased thermal stability of TAFI in the presence of heparin,
or both. The aim of the current study is to develop TAFI mutants impaired in heparin
binding, and to determine the effect of this impairment on plasmin-mediated activation of
TAFI and thermal stability of TAFIa in the presence of heparin.
The specific objectives of the current study are as follows:
1. Construction and expression of a series of TAFI variants.
2. Evaluation of binding of TAFI variants to heparin using an affinity
chromatography approach.
3. Characterization of activation kinetics of the TAFI variants by plasmin in the
presence and absence of heparin.
4. Characterization of the thermal stability of each TAFI variant in the presence and
absence of heparin.

22

Chapter 2
Materials and Methods

Materials
The synthetic carboxypeptidase substrate anisylazoformyarginine (AAFR) was
obtained from Bachem Americas Inc (Torrance, CA, US).The plasmin inhibitor Dvalylphenylalanyllysyl chloromethylketone (VFKck), the TAFIa inhibitor DL-2mercaptomethyl-3-guanidinoethylthiopropanoic acid (Plummer’s inhibitor) and the
thrombin inhibitor D-phenylalanylprolylarginyl chloromethylketone (PPAck) were
purchased from Calbiochem (San Diego, CA, US). Heparin sodium salt from porcine
intestinal mucosa and heparin-agarose type I saline suspensionwere purchased from
Sigma-Aldrich (Oakville, ON, CA). QuikChange mutagenesis kit was purchased from
Stratagene (La Jolla, CA, US). Restriction enzymes were purchased from New England
Biolabs (Mississauga, ON, CA). Oligonucleotides for mutagenesis were purchased from
Integrated DNA Technologies, Inc. (Coralville, IA, US). Dulbecco’s modified Eagle’s
medium/nutrient mixture F-12, Opti-MEM, Trypsin-EDTA, and
penicillin/streptomyocin/fungizone (PSF) wereobtained from Gibco/Invitrogen
(Burlington, ON, CA). Newborn calf serum (NCS) was obtained from Sigma-Aldrich
Canada Ltd (Oakville, ON, CA). Effectene transfection reagent was purchased from
Qiagen (Toronto, ON, CA). Methotrexate was purchased from Mayne Pharma (Montreal,
QC, CA). Amicon ultra-4 Centrifugal filter units, MWCO 10kDa were purchased from
Millipore (Billerica, MA, US). Thrombin, rabbit-lung TM and plasmin were obtained
from Haematologic Technologies (Essex Junction, VT, US). Polyclonal sheep anti-human
TAFI antibody was purchased from Affinity Biologicals (Ancaster, ON, CA), polyclonal
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rabbit anti-sheep antibody was purchased from ThermoFisher Scientific (Ottawa, ON,
CA). Enhanced chemiluminescent western blotting substrate was purchased from Thermo
Scientific Pierce Biology Products (Rockford, Illinois, US). Monoclonal anti-TAFI
antibody MA-T4E3 (purchased from Dr. Ann Gils’ laboratory, Leuven, Belgium) was
coupled to CNBr -activated Sepharose 4B (GE Healthcare Life Sciences, Mississauga,
ON, CA) according to the manufacturer’s instructions (2-6 mg antibody/mL resin).
Western blot imaging was done using Alpha Inotech Fluor Chem Q imager.
Spectrophotometry experiments were performed using a SpectraMax Plus 384
spectrophotometer.
Construction of TAFI Mutants
Mutagenesis was carried out using the Quik-Change mutagenesis kit (Stratagene)
as per the manufacturer’s standard protocol. In all cases, the template for the mutagenesis
was TAFI-pNUT, which contains a cDNA encoding human TAFI that has threonine at
positions 147 and 325. TAFI variants with threonine at 325 have a half-life of about 8
minutes whereas isoleucine at this position can increase half-life to about 15 minutes [55].
The presence of the mutations was verified by DNA sequence analysis. Creation of the
variant R320A/K324A was carried out by Ashley Kellam prior to my arrival in the
laboratory. Creation of R15A was carried out by Tanya Marar.
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Table 2-1 Primer design used for construction of the variants used in this study.
Sense strand of each primer is shown. Location of the primer binding region is indicated
by the number above the primer sequence. Nucleotides that are mismatched between the
primer and template are underlined.
Variant
Primers
K327A

1046
5’TTCGTGCTATTGAGAAAACTAGTGCAAATACCAGGTATACACATGGCC3’

K327A/R330A

1046
5’TTCGTGCTATTGAGAAACTAGTGCAAATACCGCGTATACACATGGCCATGGCTCAG3’

H308F

991
5’ ACACGAAGTAAAAGCAAAGACTTTGAGGAACTGTCTCTAGTAGC3’

K306A

986
5’ CCTATACACGAAGTAAAAGCGCAGACCATGAGGAACTGTCTC 3’

K212A

704
5’GTTATGACTACTCATGGAAAGCGAATCGAATGTGGAGAAAG3’

K211Q/K212Q

697
5’ GTGGACGGTTATGACTACTCATGGCAACAGAATCGAATGTGGAGAAAGAACCG 3’

R320A/K324A

1020
5’ACTGTCTCTAGTAGCCAGTGAAGCAGTTGCTGCTATTGAGGCAACTAGTAAAAATACC 3’

R15A

110
5'-TAGCTGCTCTTCCTAGAACCTCTGCGCAAGTTCAAGTTCT-3'

K59A

240
5’AAATGCATCTGATGTCGACAATGTGGCAGCCCATTTAAATGTGAGC3’

S316A

1017
5'-GGAACTGTCTCTAGTAGCCGCTGAAGCAGTTCGTGCTATT-3'

S249A/S251A

218
5'-GTGAGGAAGGTGCATCCGCTTCCGCATGCTCGGAAACCTAC-3'
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Expression and Purification of Recombinant TAFI Variants
BHK cells were cultured in complete medium (DMEM/F12 containing 5% (v/v)
NCS and 1% (v/v) PSF) in a humidified incubator at 37°C in a 95% air/5% CO 2
atmosphere. Expression plasmids encoding the respective TAFI variants were transfected
into cells using Effectene reagent, employing 2 μg plasmid DNA and 60 μL of
transfection reagent per 100 mm plate of cells. After 24 h incubation with the transfection
mixture, the cells were then cultured in complete medium containing 400 μM
methotrexate for approximately 2 weeks, with the medium changed every other day, for
the selection of stable cell lines expressing the respective recombinant TAFI variants. For
recombinant TAFI production, stably expressing lines were cultured in triple flasks (500
cm2, Nunc, Roskilde, Denmark) in Opti-MEM containing 1% (v/v) PSF and 40 μM
ZnCl . Medium was collected every 72 h and replaced with fresh medium. Harvested
2

medium was centrifuged at 3000 × g for 5 minutes to pellet cell debris, supplemented
with Tris-HCl, pH 8.0 (to 5 mM), reduced glutathione (to 0.5 mM) and
phenylmethanesulphonylfluoride (PMSF) to (2 μM) and stored at -20°C. To purify the
TAFI variants, conditioned medium was passed through a 0.22 µm filter and then over a 1
mL MA-T4E3-Sepharose column at 4°C. The column was washed with a 100 ml of
HBST (20 mM HEPES pH 7.4, 150 mM NaCl, 0.01% (v/v) Tween 80). TAFI that was
bound to the column was eluted with 1-mL aliquots of 0.2 M glycine pH 3. Fractions
were collected into 0.5-mL aliquots of 1M Tris-HCl, pH 8. Protein-containing fractions
were pooled, and then were concentrated, and exchanged into HBST using Amicon ultra4 Centrifugal filter units, MWCO 10kDa. Purified and concentrated TAFI was quantified
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by measurement of absorbance at 280 nm (ε1%, 280 = 26.4, Mr= 60,000), aliquoted and
stored at -70°C.

Binding of TAFI to Heparin
A 1-ml heparin-agarose column was prepared by equilibrating the column with 10
column volumes of HBS. TAFI (0.00025 mg) was applied to the column. TAFI was then
eluted with 12 fractions (200 µL each) of HBS, followed by 12 fractions of HBS
containing heparin (0.177 U/µL). TAFI content in each fraction was determined through
SDS-PAGE and western blotting.

Thermal Stability of TAFI in the Presence and Absence of Heparin.
Purified recombinant TAFI variants (1 μM) were activated by incubation with
thrombin (25 nM). TM (100 nM), CaCl2 (5mM) in HBST at 24°C for 15 min. The
thrombin was then quenched by the addition of PPAck (to 1 μM). Activated TAFI was
divided into aliquots corresponding to various time points and incubated at 37°C in the
presence or absence of heparin (0.6 U/µL). At each time point, aliquots were placed on
ice. Following the final time point, 15 μl of each aliquot was mixed with 35 μl HBST and
50 μl AAFR (120 μM final concentration) in a microtitre plate, and the initial rates of
substrate hydrolysis were measured at 350 nm. The carboxypeptidase B function of
TAFIa hydrolyzes AAFR according to the following reaction:
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(Scheme 1)
Before the anisylazoformyl moiety is removed, AAFR strongly absorbs at 350 nm. Upon
the removal of this moiety, the resultant products do not absorb at this wavelength.
The hydrolysis rate was directly related to the activity of TAFIa and related to the
initial TAFIa activity by dividing the initial hydrolysis rate by the hydrolysis rate at each
respective time point. This relationship was plotted as a function of time. Non-linear
regression to the equation for first-order exponential decay (SigmaPlot 11.0, SPSS Inc.,
Chicago, IL) was used to fit the data in order to obtain rate constants from which the halflives of each variant could be calculated:
[TAFIa]=[TAFIa]0*e-k*t

(Equation 1)

Where [TAFIa]0 is the initial TAFIa concentration,[TAFIa] is the residual concentration at
each time point, and k, is the first order decay constant obtained from the non-linear
regression in SigmaPlot.
Half-life is defined as the time when [TAFIa]=0.5*[TAFIa]0,
0.5*[TAFI]0=[ TAFIa]0*e-k*t
0.5=e-k*t
t=-ln(0.5)/k

(Equation 2)
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The half-life of each variant is thus obtained by substituting the decay constant k into the
equation (2).

Kinetics of Activation of TAFI Mutants by Plasmin in the Presence or Absence of
Heparin.
For activation by plasmin, a range of concentrations of the TAFI variants (0.010.1 µM) was incubated with 25nM plasmin, and 5 µM Plummer’s inhibitor in the
presence or absence of heparin 0.2 U/µL for 12 min at 24ºC . Reactions were stopped by
the addition of VFKck (1µM final concentration). SDS-PAGE sample buffer (0.2 M TrisHCl, 8% SDS, 40% Glycerol, 0.08% bromophenol blue) was immediately added to the
samples. Samples were analyzed by SDS-PAGE and western blotting with the goat antihuman TAFI polyclonal antibody. A TAFIa standard curve was prepared along with each
kinetic experiment. A TAFIa standard solution was made by activating 1 µM TAFI for 10
min at 24 ˚C in the presence of HBST, 25 nm thrombin, 100 nm thrombomodulin, 5 mM
CaCl2 to achieve complete activation of TAFI to TAFIa. TAFIa was then serially diluted
to concentrations of 0.0053-0.04 µM and then subjected to SDS-PAGE and western
blotting like the kinetic samples. For a given experiment, all blots containing standards
and samples were processed simultaneously for visualization of immunoreactive bands or
order for the standard curve to be applicable to the samples. The densities of the 35 kDa
TAFIa and 25 kDa TAFIai bands were quantified using AlphaView SA software. A
standard curve was constructed by plotting the density of each standard TAFIa sample
against its concentration. The TAFIa concentrations formed in each kinetic run were thus
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obtained by interpolating the densities on the standard curve. The concentration of TAFIa
formed was then converted to the rate of TAFIa formation (moles of TAFIa formed per
second per mole of plasmin). The data were fit to the Michaelis-Menten equation
(Sigmaplot 11.0, SPSS Inc., Chicago, IL).
V=kcat[E]T[S]/(KM+[S])

(Equation 3)

Although the data were fit to the Michaelis-Menten equation, the kcat and Km values that
will be reported are apparent values, and referred to as kcat(app) Km(app) respectively. Since
the substrate concentrations and the enzyme concentrations are comparable, the
Michaelis-Menten assumption of a steady state [ES] and saturations of E with S do not
hold. In an attempt to account for this, the data were fit to the quadratic form of the
Michaelis-Menten equation (Equation 4), but the data sets did not give a reasonable fit to
this equation. Thus, the Michaelis-Menten equation was employed to give apparent
constants that can at least be operationally compared to each other.
V= kcat (0.5* (Km +[E]T+[S]T-((Km+[S]T)2-4*([E]T[S]T))1/2))
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(Equation 4)

Chapter 3
Results

3.1 Construction and Expression of TAFI Variants
In order to assess potential heparin binding sites of TAFI, a number of TAFI
variants were designed that contained mutations of potential residues involved in heparin
binding. Based on the crystal structure of bovine TAFI in the presence of sulfate ions
[50],where the negatively charged sulfate ions, in complex with TAFI, were suggested to
represent potential heparin binding sites, Anand and coworkers identified four potential
regions of heparin binding. Of these, we selected two of the regions for our mutagenesis
(Fig 3-1; Table 3-1). The first region identified by Anand and coworkers was Trp210Ser221. It also was previously reported that this region shows sequence similarity with
other glycosaminoglycan binding proteins [43,51]. In the crystal structure of bovine
TAFI, one out of 22 sulfate molecules was bound to this region at Lysine 212 [51]. The
second region that had a set of bound sulfates is the region running from the instability
region to the active site cleft. However, it was suggested that heparin binding in this
region would actually hinder binding of TAFI substrates, and thus interfere with
carboxypeptidase activity of TAFI. Therefore, we did not pursue mutagenesis in this
region. The third region of interest was Ser305-His335, which is the instability region of
TAFI. Binding of heparin to this region would explain the increased half-life of TAFI and
therefore a number of mutations were made in this region. Five sulfates were also bound
to the pro-domain. However, binding of heparin to this region would not explain the
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increased stability of TAFI [51]. Regions Trp210-Ser211 and Ser305-His335 were
therefore the focus of this study. Table 3-1 summarizes the variants that were pursued.
Figure 3-1 shows an alignment of bovine and human TAFI.

Figure 3-1. Alignment of bovine and human TAFI amino acid sequences. Two
regions of interest, that contained bound sulfates, are circled, with arrows indicating the
residues that were mutated in this study.
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Table 3-1. Recombinant TAFI variants used in this study. The majority of the
mutations were made on based on the bound sulfates, with the exception of
K211Q/K212Q, and R320A/K324A.
Variant

Region

Rationale

K212A

Sequence similarity with GAG
binding proteins

Bound sulfate

K211Q/K212Q Sequence similarity with
heparin GAG binding proteins
K327A

Instability region

Sulfate may be bound to the
neighbouring lysine in human
TAFI
Bound sulfate

K327A/R330A Instability region

Bound sulfate

H308F

Instability region

Bound sulfate

K306A

Instability region

Bound sulfate

R320A/K324A Instability region

Charged, exposed residues. In
close proximity to sulfatebinding residues that are not
conserved between bovine and
human TAFI.
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Variant K212A was pursued because a sulfate molecule was bound to lysine 212 in the
bovine TAFI crystal structure. Since the three-dimensional shape of the bovine TAFI
molecule slightly differs from that of the human TAFI, it is possible that that the sulfate
molecule could bind to the neighbouring lysine residue, 211. Therefore, both lysines, 211
and 212, were mutated. Originally, the double mutation of the two lysine residues (211,
212) was intended to be to two alanine residues. However these mutations did not result
in detectable secreted protein. Therefore both lysine residues were mutated to glutamine
residues, as this polar residue might be better accommodated on the surface of the protein.
Variants K327A, K327A/R330A, H308F, K306A were pursued due to the binding of the
sulfate ions to these residues. The majority of these variants contained a mutation to an
alanine, with the exception of the H308F, where the charged histidine residue was
mutated to phenylalanine to preserve the presence of an aromatic ring. A number of
sulfate ions were bound to residues, in the instability region, that are not conserved
between human and bovine TAFI, therefore neighbouring exposed charged residues, such
as arginine 320 and lysine 324 were mutated to an alanine.

34

3.2 Binding of TAFI variants to heparin-agarose
Both bovine and human TAFI have been shown to bind heparin, through the use
of heparin-sepharose, as the majority of the protein was eluted with high salt
concentrations [52]. We employed a similar method. However, after the protein was
applied to the column, and following the HBS wash, bound proteins were eluted with
HBS containing heparin, to more conclusively demonstrate spesific binding of TAFI to
heparin. Figure 3-2 summarizes the elution profile of wild-type TAFI and other TAFI
variants. As predicted, wild-type TAFI remained bound to heparin throughout a series of
wash fractions (2.4X column volumes), and was eluted with the addition of heparin.To
demonstrate the specificity of TAFI binding to the immobilized heparin, rather than the
agarose itself, a similar binding experiment was conducted using a column containing
unconjugated agarose beads. TAFI eluted in the wash fractions and heparin did not result
in any further elution of TAFI, suggesting that none of the applied TAFI bound nonspecifically to agarose. Some of the variants exhibit an elution profile similar to wildtype. However, K211A, K211Q/K212Q, K327A, as well as K327A/R330A exhibit a two
peak elution pattern, indicating either a reduced affinity for heparin or that there may be
both a binding and a non-binding fractions. Variant R320A/K324A appers to have lower
affinity for heparin-agarose, as it is almost entirely eluted in the HBS was
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Figure 3-2 Binding of TAFI variants to heparin-agarose. TAFI was applied to a heparinagarose column, followed by an HBS wash, and heparin wash. The elution profile of each
variant is representative of its affinity for heparin-agarose. Wild-type TAFI was also applied to
an agarose column to account for heparin-independant binding to agarose. The detection of
TAFI content in each fraction was done through western blotting

3.3 Kinetics of activation of TAFI variants by plasmin in absence and presence of
heparin
The activation of TAFI by plasmin is accelerated in the presence of heparin, an
effect expressed by a 5.9-fold increase in kcat and a 2.7-fold decrease in Km [43].The
contribution that several potential heparin-binding residues have on the acceleration of
TAFI activation by plasmin in the presence heparin was analyzed by western blot
analysis. Table 3-2 and Figure 3-3 summarize the kinetic parameters of activation of
TAFI variants by plasmin in absence and presence of heparin. To varying degrees,
activation of all of the variants by plasmin is accelerated when heparin is present,
indicating that none of the mutated residues completely abolish the stimulating effect
heparin has on TAFI activation by plasmin. Variants K212A, K327A/R330A, and H308F
exhibit the greatest enhancement of catalytic efficiency in the presence of heparin, and in
each case this reflects a lower catalytic efficiency in the absence of heparin. The degree of
rate enhancement by heparin is considerably lower for variants K211Q/K212Q and
R320A/K324A, with the fold difference in the catalytic efficiency being 1.3- and 1.2-fold
respectively, compared to wild-type, which is 1.5-fold. Compared to wild-type TAFI and
most of the other variants, a substantial increase in Km was observed for each of these
variants both in the absence and presence of heparin, which indicates a reduced affinity of
plasmin for these variants. Although variant K306A does not show a difference with
wild-type with respect to fold increase in catalytic efficiency in the presence of heparin,
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inspection of Figure 3-3f does show a clear decrease in the magnitude of the effect of
heparin, compared to wild-type TAFI and most other variants. We suspect that the
Km(app) of this variant in the absence of heparin has been over-estimated: at these low
rates, we are approaching the limit of sensitivity of the western blot assay.
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Table 3-2. Activation of TAFI variants by plasmin in the absence and presence of
heparin. kcat (app) and Km (app) values were determined from the data in Figure 3-3. The
standard error of kcat (app) and KM (app) were estimated by the regression algorithm in
SigmaPlot 11.
Variant

kcat(app) (s-1)

kcat(app)/Km(app)(µM-1. s-1)

Km (app) (µM)

+heparin

-heparin

+heparin

-heparin

+heparin

-heparin

TAFIwt

0.00190±0.00004

0.00070±0.00007

0.036±0.002

0.021±0.0
05

0.051

0.033

kcat(app)/
Km(app)
fold
increase
1.5

K327A

0.00220±0.00050

0.00060±0.00006

0.040±0.018

0.018±0.0
04

0.053

0.032

1.6

3

K327A/
R330A

0.00190±0.00030

0.00100±0.00004

0.049±0.013

0.063±0.0
04

0.039

0.016

2.4

3

H308F

0.00190±0.00010

0.00100±0.00006

0.032±0.005

0.039±0.0
10

0.059

0.025

2.3

3

K212A

0.00280±0.00060

0.00110±0.0004

0.067±0.003

0.041

0.015

2.7

3

K211Q/
K212Q
R320A/
K324A
K306A

0.00150±0.00030

0.00090±0.00020

0.096±0.031

0.014

0.011

1.3

3

0.00720±0.00140

0.00330±0.00010

0.309±0.072

0.023

0.019

1.2

2

0.00230±0.00040

0.00190±0.00010

0.122±0.031

0.071±0.0
09
0.076±0.0
29
0.168±0.0
68
0.157±0.0
17

0.019

0.012

1.6

2
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Figure 3-3 Activation of TAFI variants by plasmin in the presence or absence of
heparin. Various concentrations of wild-type TAFI (a), K327A (b), K327A/R330A (c),
H308F (d), K212A (e), K211Q/K212Q (f), R320A/K324A (g), K306A (h) were
incubated with 25 nM plasmin, in the presence (circle) or absence (cross) of 0.02 U/µL
heparin for 12 min at room temperature. The rates of activation were calculated and the
data were fit to the Michaelis-Menten equation. Each point represents the mean of at least
two experiments, with the error bars representing the standard error of the mean (for n≥3)
or the range of the data (for n=2). The lines are regression lines calculated from the fit
parameters.
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3.4 Thermal Stability of TAFI variants in the Presence and Absence of Heparin
Activated TAFI is a highly unstable enzyme. Depending on the isoform, the halflife of TAFI is 8-15 minutes [55]. It has been previously shown that thermal instability of
TAFI is responsible for the inactivation of the enzyme and influences its antifibrinolytic
potential [48]. Heparin has been shown to increase the half-life of TAFIa [43]. Although
the study of the effect of heparin on the stability of TAFIa was previously done at 25˚C,
increasing the half-life from 74 min to 170 min [43], we hypothesized that heparin would
have a similar stabilizing effect at 37˚C. It was determined that heparin does stabilize
TAFIa at body temperature, increasing the half-life from for the wild-type enzyme from
6.4 minutes to 10.8 minutes (Table 3-4). The specific enzymatic activity of all of the
variants ranged between 68 % of wild-type (K211Q/K212Q) and 124% of wild-type
(R320A/R330A), trends that were not markedly altered by the presence of heparin (data
not shown).The contribution of the various residues to the TAFIa stabilizing effect of
heparin was determined. Table 3-3 and Figure 3-4 summarise the half-lives of wild-type
TAFIa compared to the TAFIa variants. Several variants were less stable than wild-type
TAFI in the absence and presence of heparin, while the R320A/K324A variant was more
stable than wild-type TAFIa in the absence of heparin. Some of the variants exhibited a
considerably reduced stabilizing effect of heparin, when compared to the wild-type
enzyme: specifically K327A, K327A/R330A, K212A, and R320A/K324A, which
corresponds to the lowest fold increase in the half-life in the presence and absence of
heparin in these variants.
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Table 3-3. The intrinsic stability of TAFIa variants in the absence and presence of
heparin at 37˚C. Decay constants estimated by the regression of the data in Figure 3-4
were used to calculate the half-lives of the TAFIa mutant in the absence and presence of
heparin. The data represent the mean of at least 2 experiments. With error representing
the standard error of the mean (for n≥3) or the range of the data for (n=2). Half-life fold
increase is a ratio between the half-life of TAFI in the presence and absence of heparin.
Variant

Half-life
+heparin(min)

Half-life
fold
increase
1.7

# of
replicates

WT

10.80 ±0.11

heparin(min)
6.41±0.53

K327A

5.87±0.14

4.73±0.42

1.3

3

K327A/R330A

5.58±0.83

4.29±0.26

1.3

3

H308F

11.80±0.61

6.64±1.52

1.7

2

K212A

6.81±0.44

5.08±0.49

1.3

4

K211Q/K212Q

8.07 ±1.16

5.11±1.10

1.6

3

K306A

8.19±2.3

4.6±0.59

1.8

4

R320A/K324A

9.89±0.60

8.51±0.97

1.2

3
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Figure 3-4 The intrinsic stability of TAFIa variants in the absence and presence of
heparin at 37˚C. WT(a), K327A(b), K327A/R330A(c), H308F(d), K212A(e),
K211Q/K212Q(f), R320A/K324A(g), K306A(h) were activated in the presence of
thrombin-TM, and incubated at 37˚C in the presence (circle) or absence (cross) of
heparin. TAFIa activity was measured at different time points. The data were fit to the
equation describing first-order exponential decay in order to determine the half-lives of
TAFIa. Each point represents the mean of at least two experiments with the error bars
representing the standard error of the mean (for n≥3) or the range of the data for (n=2).
The lines are regression lines calculated from the fit parameters.
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Chapter 4
Discussion and Conclusion

4.1 Role of Glycosaminoglycans in the TAFI Pathway
TAFI pathway has been shown to play a significant role in fibrinolysis by
removing carboxyl-terminal lysines from partially degraded fibrin thus reducing the
ability of this material to promote the activation of plasminogen and the conversion of
Glu-plasminogen to Lys-plasminogen, as well as to protect plasmin from consumption by
antiplasmin [32,66]. To elicit these effects, TAFI zymogen has to be activated by
thrombin, thrombin/thrombomodulin complex, or plasmin [34,41]. Even though the TAFI
pathway has been studied extensively, the contribution of these activators on the localized
activation of TAFI remains unknown. There is a possibility that none of these activators
are the exclusive, physiologically relevant, activator of TAFI. Even though the catalytic
efficiency of thrombin-thrombomodulin activation of TAFI is much greater than that for
thrombin alone or plasmin [41], the characteristics of the site where the activation takes
place may be the determining factor of what is the physiologically-relevant activator of
TAFI at that site. High concentrations of glycosaminoglycans can be found at a site of a
vascular injury, due to the exposure of the extracellular matrix components. Due to an
increase in catalytic efficiency of plasmin-mediated activation of TAFI in the presence of
glycosaminoglycans, it is fair to hypothesize that plasmin is an important activator at a
site where there is a high concentration of glycosaminoglycans [43]. The majority of the
endothelial cell cofactor thrombomodulin, however, would be absent at the site of a
vascular injury, further emphasizing the importance of plasmin-mediated mechanism of
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TAFI activation [43]. On the other hand, in the situation of an intact endothelial cell
surface, thrombin/thrombomodulin may be main activator of TAFI [44].
Due to the function of TAFI in regulation of the balance between the coagulation
and the fibrinolysis, understanding the TAFI pathway would aid in the development of
either thrombosis or bleeding disorder therapeutics. Current therapy for thrombotic
disorders heavily relies on the use of heparin, and other heparin-related drugs [89,90].
However, heparin therapy has been complicated with the determination of appropriate
dosage, as well as heparin-induced thrombocytopenia (HIT), resulting in increased
thrombosis [90,91]. Another potential problem that could arise from heparin therapy is
increased plasmin-mediated activation of TAFI, as well as increased stability of TAFIa
[43], which would result in decrease in fibrinolysis and therefore antagonize the
anticoagulant properties of heparin.
The focus of the present study was to develop TAFI variants that are resistant to
heparin binding and could be used to explore contribution of heparin on activation and
stability of TAFI in vitro, and eventually in vivo. The number and location of sites on
TAFI that bind heparin are completely unknown, as is the relationship between these sites
and the observed effects of heparin on TAFI activation and TAFIa stability. Guided by Xray crystallographic data on the structure of TAFI, in the presence of sulfate ions, as well
as by similarity of certain sequences in TAFI to heparin-binding proteins, we have
mutated selected residues in the Trp210-Ser221, and Ser305-His335 regions. However, it
should be noted that the binding of individual sulfates may not necessarily represent bona
fide heparin-protein interactions, as heparin itself is a polymer of sulfated glycosidic
units. Therefore it is possible that some of the residues that were associated with a sulfate
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ion, are not physiologically relevant as heparin binding sites. This might explain why
mutation of some of the sulfate-bound residues had no effect on heparin binding.
Molecular docking of a single heparin molecule to TAFI may be a better model for TAFI
interaction with heparin. Nonetheless we anticipated this model would be indicative of
some of the heparin binding sites and would lead us to variants resistant to heparin
binding and thus resistant to enhanced activation by plasmin and to increased thermal
stability of TAFIa due to heparin. As elaborated below, the results reveal a rather
complex scenario where no one site definitively eliminated both heparin binding as well
as the effects of heparin on TAFI activation and/or TAFIa stability. Several of the
variants displayed impaired heparin binding, as evidenced by a two-peak elution pattern
where some of the TAFI eluted in the wash fractions of the heparin-agarose column with
the remainder being specifically eluted by heparin. Some of these variants showed
reduced plasmin activation acceleration by heparin, while others did not. Likewise, some
of these variants impaired in heparin binding showed decreased stabilization by heparin
but others did not. One variant, R320A/K324A, did exhibit a drastically reduced affinity
for heparin, with almost all of the protein eluting in the wash fractions. This variant was
impaired in both acceleration of activation as well as in enzyme stabilization by heparin,
yet some residual effects of heparin remained. Altogether, these findings shed new light
on the nature of the TAFI-heparin interaction, and will aid us in future understanding of
significance of TAFI binding to heparin and other glycosaminoglycans, and the effect of
the binding on the activation and stability of the enzyme. This knowledge will lead to
further understanding of modulation of the TAFI pathway via heparin and other
glycosaminoglycans.
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4.2 Binding of TAFI variants to heparin-agarose.
To estimate the contribution of various residues on the binding of TAFI to
heparin, we employed a heparin-agarose column. We hypothesized that if the mutated
residue is critical to heparin binding of TAFI, the protein will be eluted from the column
more readily than the wild-type protein. In fact, wild-type TAFI remained bound to the
column until the addition of heparin, while one variant, R320A/K324A, was almost
entirely eluted from the column in the wash fractions with very little remaining for elution
by heparin. On the other hand, several of variants, namely K211A, K211Q/K212Q,
K327A, and K327A/R330A, exhibited a two peak elution profile with differing
characteristic amounts of TAFI eluted in the wash fractions. Each of these mutants
displayed a relatively consistent elution pattern, when compared between repeated
experiments. The reason for the two peak elution pattern is unknown. However, it can be
hypothesized that it results from either a reduced affinity of the variant for the column
such that a fraction remains unbound under these conditions, or the presence of two
fractions of TAFI with different affinities for the heparin-agarose.
The source of these two fractions may be the existence of two difference different
glycoforms of TAFI. A previous report on recombinant antithrombin showed that there
are two major glycoforms of antithrombin present due to both differential usage of the
one of the glycosylation sites, as well heterogeneous glycosylation at the remaining
sites.Those glycoforms varied in the affinity to the heparin-agarose up to 10-fold [97].
TAFI contains four sites of N-linked glycosylation, all of which are in the activation
domain of TAFI and all of which appear to be used in all molecules of both recombinant
and plasma-derived TAFI [39]. One group reported that there is an additional N-linked
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glycosylation site, not utilized in all molecules of TAFI, in the catalytic domain of
TAFI[38]. However, subsequent crystallographic data [40] comprehensively debunked
this notion as the Asn219 residue implicated is buried within the core of the catalytic
domain. It has been shown that there is microheterogeneity in three of the N-linked
glycans while the fourth is homogeneous [38]. Mutation of each of four glycosylation
sites on TAFI could potentially determine which of the sites might contribute to potential
micoheterogeneity affecting heparin binding. Alternatively, mass spectrometric analysis
of the glycans present in the binding and non-binding TAFI fractions could be performed.
However, it is difficult at this time to rationalize how mutations in the catalytic domain of
TAFI could influence the extent of microheterogeneity in the N-linked glycans on the
activation peptide.
We did rule out the third possibility for the presence of two binding fractions: that
the TAFI-binding capacity of the heparin column was saturated by the amount of TAFI
applied. Two factors suggest against this possibility. First, several of the variants
including wild-type TAFI bound to the column, and eluted in a single peak, despite all
variants being applied in the same amounts to same-sized columns. In addition, during the
optimization of this experiment, even after lowering the amount of applied TAFI by
nearly 10-fold, we still observed a two peak elution pattern for some of the variants. To
further establish that the column is not saturated, the amount of TAFI for variants in
question was lower by 1.5-fold. However, a similar elution pattern was observed (data not
shown).
The next step in comparing the contribution of various residues on binding of
TAFI to heparin, would be to perform equilibrium binding experiments to determine the
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dissociation constant (Kd) of the TAFI variants for binding to heparin. We did investigate
two different approaches to measuring this value. First, we purchased fluorescentlylabeled heparin and titrated this material with TAFI while measuring the fluorescence
intensity. If binding to TAFI increased or decreased the quantum yield of the heparinbound flourophore, the data could have been used to arrive at a Kd. However, no change
in fluorescence was observed, suggesting that binding of TAFI did not alter the chemical
environment of the fluorophore. Similar solution-phase experiments can be envisaged,
such as using fluorescently-labeling TAFI, measuring changes in fluorescence anisotropy,
or measuring changes in light-scattering intensity.
We also attempted a equilibrium binding analysis using a ligand binding assay
where heparin-agarose was incubated with various concentrations of TAFI; following
pelleting of the heparin-agarose by brief centrifugation, the TAFI concentration in the
supernatant (representing the unbound fraction) was measured using either western
blotting or enzyme-linked immunosorbent assay (ELISA). The results we observed are
summarized in the Appendix. However, clear evidence for specific, saturable binding
could not be obtained within the limited timeframe available; clearly, more optimization
for the experiment is needed.
Overall, it can be concluded that variant R320A/R324A exhibited the lowest
affinity for heparin agarose, as it was almost entirely eluted in a single peak, during the
wash. Variants K211A, K211Q/K212Q, K327A, and K327A/R330A eluted in a two-peak
manner.
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4.3 Kinetics of activation of TAFI variants by plasmin in absence and presence of
heparin
Plasmin is an active form of the proenzyme plasminogen,that results from the
cleavage of plasminogen Arg561-Val562 peptide bond [68]. It was previously reported
that plasmin-mediated activation of TAFI is accelerated in the presence of heparin [43].
Mao and coworkers activated TAFI with either thrombin or plasmin in the presence and
absence of heparin. They found that heparin had no effect on activation of TAFI by
thrombin, while enhancing catalytic efficiency of plasmin-mediated activation of TAFI
16 fold [43]. In the current study we examined the contribution of various residues on
plasmin-mediated activation in the presence or absence of heparin. We found that all of
the TAFI variants exhibited accelerated activation by plasmin in the presence of heparin,
to a certain degree. While Mao and coworkers observed a 16-fold increase in catalytic
efficiency in the presence of heparin in the case of the wild-type enzyme, we determined
the catalytic fold increase to be 1.5. However we observed kcat(app) values in the presence
and absence of heparin to be 0.00190 s-1 and 0.00070 s-1 respectively. These values are
similar to those reported by Mao and coworkers, 0.0026 s-1 and 0.00044 s-1 in the
presence and absence of heparin respectively. In the current study, we found that
Km(app)values were similar, within error, in the presence and absence and heparin. Mao
and coworkers found a decrease in Km in the presence of heparin, while we tended to
observe an increase, accounting for the differences in fold increase in catalytic efficiency
between the two studies. It is possible, from inspection of our data, especially in the
absence of heparin, that we were approaching the limits of sensitivity of our western blot
assay and thus may have overestimated the extent of TAFI activation at low
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concentrations of substrate, thus artificially decreasing Km(app). Indeed, our Km in the
absence of heparin for wild-type TAFI was 0.021 µM, versus 0.055 µM reported by Mao
and coworkers. To more accurately estimate Km, we would have had to use even lower
concentrations of TAFI which would have further compromised the accuracy of our
assay. Moreover, we were not able to fit our data to the quadratic form of the MichaelisMenten equation, which may have altered our estimates of kcat and Km. Nonetheless, our
kinetic data at higher TAFI concentrations clearly show a marked effect of heparin on the
rate of TAFI activation. By examining the kinetic data (Fig 3-3) and the obtained kinetic
parameters (Table 3-2) for plasmin-mediated activation of different variants, it is evident
that the lowest degree of rate enhancement is exhibited by variants K211Q/K212Q and
R320A/K324A. However, this is not well represented in a reduced fold kcat/Km difference
likely due, as argued above, that the true extent of enhancement of catalytic efficiency of
wild-type

TAFI

is

underestimated.

Nonetheless,

variants

K211Q/K212Q

and

R320A/K324A exhibit the lowest fold difference in kcat/Km between plasmin-mediated
activation in the presence or absence of heparin. Although the fold difference in kcat/Km in
the presence and absence of heparin in the case of mutant K306A is similar to that of
wild-type, through the analysis of the Figure 3-3f, it appears that heparin has a reduced
effect on plasmin-mediated activation of this variant. This could be due to the
aforementioned inaccuracy of Km(app) estimation. It is evident that the rate of plasminmediated activation of variants K211Q/K212Q and R320A/K324A, as well as K306A, is
substantially lower, an effect attributable mostly to higher Km(app) values for these
variants. These data suggest that these residues play a role in interacting with plasmin.
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Plasmin consists of two disulfide-bonded chains. The light chain consists of a
trypsin-like protease domain; plasmin displays comparatively broad substrate specificity
and the protease domain itself makes limited contacts with the substrate outside of the
residues surrounding the scissile bond. The heavy chain, however, consists of five kringle
domains. Kringle domains are tri-looped structures, containing six invariant disulfide
bonds,that are thought to mediate protein-protein interactions. Indeed, kringles 1 and 4 of
plasmin contain high affinity lysine-binding sites that participate in maintaining the
closed conformation of native plasminogen and in binding interactions with basic
residues on substrates such as fibrin and antiplasmin [69,99]. Although there are few
reports characterizing plasmin-TAFI interactions, several residues have been identified to
be important in the formation of the TAFI-plasmin complex, and therefore activation of
TAFI by plasmin . These residues are lysine 268, serine 272, arginine 276, threonine 147,
and phenylalanine113. Lysine 268, serine 272, arginine 276 are important exclusively in
plasmin binding to TAFI, while the rest of these residues are implicated in activation of
TAFI by both plasmin and thrombin [100]. The fact that not all of these residues are
lysines is explained by the fact that the mutations were made on the basis of binding sites
mapped for antibodies against TAFI that specifically impaired activation by plasmin or
thrombin; the effect of the mutations on recognition by these proteases may be due to
local alterations in protein structure. Figure 4-1a exhibits the positioning of these residues
in three-dimensional model of TAFI. Since variants K211Q/K212Q, R320A/K324A, and
K306A exhibit a larger Km (app), there is a possibility that these residues participate in
plasmin binding to TAFI. Figure 4-1b displays the positioning of these residues in
relation to each other, while Figure 4-1 c, d, and e display the positioning of these
residues in relation to the residues that have been shown to participate in the binding of
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TAFI to plasmin. Although these K211, K212, R320, K324, and K306 are not positioned
in close proximity to the residues that have been implicated in plasmin in plasmin
binding, nor are the previously-described residues important for plasmin binding, in
respect to each other (Fig 4-1). From Fig 4-1 it is also evident that K211, K212, R320,
K324, and K306 are exposed charged residues that could potentially interact with the
kringle domains of plasmin.
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Figure 4-1. Location of residues implicated in decreased activation of TAFI by
plasmin. Images were generated using Cn3D software (pdb file:3D66 of human TAFI)
Activation peptide is demonstrated in cyan, catalytic domain is in purple. TAFI cleavage
site by thrombin and plasmin, Arg92, is represented in red, indicated with an arrow. a)
Location of residues previously reported to be critical for plasmin binding to TAFI
(yellow). b) Location of the residues mutated in variants that exhibit lower affinity to
plasmin (green). c)-e) Location of each individual variant in b) in relation to residues in a)

a)
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Lys 211/Lys212
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Lys 306
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Arg320/Lys324
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There was not complete concordance between impaired heparin binding and an
effect on heparin-accelerated activation by plasmin. The variants K212A, K327A, and
K327A/R330A show impaired heparin binding, yet essentially normal responses to
heparin in the plasmin activation assay. The K211Q/K212Q and R320A/K324A variants
did exhibit a lower fold difference in kcat/KM in the presence or absence of heparin, which
could potentially be due to the lower affinity of these variants for heparin. Notably, The
K211Q/K212Q, R320A/K324A, and K306A variants were also impaired in respect to
plasmin activation, when compared to wild-type TAFI, which complicates interpretation
of the results. Is the defect in heparin binding responsible for the lower stimulation of
activation, or does the apparently impaired interaction of the variants with plasmin impair
the ability of heparin to have its stimulatory effect? In the case of thrombin inhibition by
antithrombin, heparin catalyzes this reaction by binding to both thrombin and
antithrombin [22,85]. It is highly likely that heparin binds to both plasmin and TAFI, thus
eliciting its accelerating effect on TAFI activation by plasmin. In that case, impaired
binding of TAFI to plasmin, would also affect heparin binding to TAFI. To further
investigate this possibility, a truncated form of plasmin can be used. Microplasmin lacks
all 5 kringles, but has an active catalytic domain [98], which, in theory, could still activate
TAFI. This approach may give an insight on whether heparin can still elicit its catalyzing
effect on plasmin-mediated activation of TAFI in a kringle-independent manner.
In addition to the above mentioned variants, a number of additional variants were
studied in respect to plasmin activation in the presence or absence of heparin. These
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variants are K59A, R12A, R15A, S316A, and S249A/S251A. Variants K59A, R12A, and
R15A were pursued based on the report that a number of sulfates were bound to the
exposed charged residues in the pro-domain [51]. The identity of these residues was not
provided, therefore, we used the Cn3D software (pdb:3D66) to explore the threedimensional shape of the TAFI molecule, and to identify exposed charged residues in the
pro-domain. Variants S316A, S249A/S251A were pursued based on another report of the
TAFI crystal structure, where sulfates were found to be associated with these residues
[52].The data for these variants are preliminary, and therefore is reported in the
Appendix; however, the replacement of these residues with an alanine residue did not
abolish the accelerating effect of heparin on TAFI activation. Further characterization of
these variants is required to determine if the accelerating effect of heparin is reduced to a
certain degree, in comparison to the wild-type TAFI.
4.4 Thermal Stability of TAFI variants in the Presence and Absence of Heparin.
Heparin, has been shown to increase thermal stability of TAFIa [43]. Mao and
coworkers established that half-life of TAFI at 25˚C was increased from 74 min to 170
min in the presence of TAFI [43]. Although they did not examine the role of heparin on
the stability of TAFIa at body temperature, we expected to see a similar effect of heparin
on the stability of TAFIa at 37˚C. Indeed, it was found that presence of heparin increased
the half-life of the wild-type enzyme from 6.41±0.53 minutes to 10.8 ±0.11 minutes. To
further examine the contribution of various residues on the stability of TAFIa in the
presence and absence of heparin, we subjected the variants in question to the same assay.
As expected, the majority of the mutations in the instability region decreased the stability
of TAFIa both in the presence and absence of heparin, when compared to the wild-type
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enzyme. Stability of the variant H308F was similar to the wild-type TAFIa, within
experimental error. The variant R320A/K324A was found to be more stable in the
absence of heparin, when compared to the wild-type TAFIa. The stability of TAFIa
depends on the dynamics of the instability region, and this double mutation could
potentially reduce the movement of this region, thus increasing stability. Lysine 324 is
also neighbouring threonine 325, which is the site of a naturally occurring single
nucleotide polymorphism. When isoleucine is substituted for threonine at this position,
the half-life of TAFIa is increased from ~8 min to ~15 min [55]. Therefore, it is possible
that the substitution of a charged residue with an uncharged alanine could potentially
have a stabilizing effect. Variant K327A, K327A/R330A, and K212A seem to be slightly
less stable in the presence and absence of heparin. When examining the effect of heparin
on the half-lives of all of the above variants, half-life fold increase is the lowest for
K327A, K327A/R330A, and K212A, and R320A/K324A. Half-life fold increase of these
variants in the presence of heparin is 1.3, compared to the wild-type enzyme, where the
half-life fold increase is 1.7. Therefore, these residues could potentially be important in
the modulation of TAFIa stability by heparin. As with the plasmin activation experiment,
there was no perfect agreement between the heparin binding data and the stability data.
While all of the variants with impaired stabilization by heparin also show reduced binding
to the heparin column, the K211Q/K212Q variant shows nearly normal stabilization by
heparin.
As in the case of plasmin activation, a number of variants were introduced in the
later stages of this study. Since variant S316A is in the instability region, while
S249A/S251A is close to the instability region, the effect of heparin on the thermal
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stability was analyzed. Preliminary results are reported in the Appendix. Although, the
data is preliminary, there was a clear effect of heparin on the stability of TAFIa in both
variants. Further studies will be needed to examine if the stability increase in the presence
of heparin is reduced compared to the wild-type enzyme.
4.5 Conclusion
In the current study we set out to examine the effect of heparin binding on the
plasmin-mediated TAFI activation and thermal stability of TAFIa. A number of TAFI
residues suspected in the participation of heparin binding were mutated with an ultimate
goal of determining variants that are resistant to heparin binding. Such variants would be
useful for assessing the importance of heparin modulation of TAFI activation and TAFIa
stability, for example in the setting of anticoagulation with heparin or in the presence
extracellular matrix. Although variants that are completely resistant to heparin binding
were not identified, we established a number of variants that are moderately impaired in
respect to heparin binding, and one, R320A/K324A that is very nearly completely
impaired in heparin binding. In addition, there was a strong, but not absolute, relationship
between the degree of impairment in heparin binding and reduction in activation or
stabilization by heparin. Therefore, it is reasonable to conclude that there are multiple
sites on TAFI for heparin binding, and that heparin binding at these different sites may be
important for different functions of heparin in respect to TAFI. Variants such as K211A,
K327A, and K327A/R330A displayed reduced binding to the heparin-agarose column
(dramatically so in the case of K327A/R330A), while still showing similar kinetic
parameters in respect to plasmin-mediated activation. The same variants exhibited the
lowest difference in the half-life of TAFIa in the presence and absence of heparin.
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However, these variants with the addition of K211Q/K212Q eluted from the heparinagarose column in two peaks, which could either be the result of lower affinity (for
example because of the elimination of one heparin binding site), or presence of two
glycoforms of TAFI. Different glycoforms may exhibit differential affinity for heparin.
Further studies are required to analyze the role of potential differential glycosalation on
the binding of these variants to heparin. Since the activation parameters were not affected
by the reduced affinity to heparin for some variants, these residues may play a role in the
stabilization of TAFI in the presence of heparin. Variants K306A, K211Q/K212Q, and
R320A/K324A seem to exhibit both a reduced effect of heparin on the activation of TAFI
by plasmin, as well as lower affinity for plasmin, due to large Km (app) of this variants.
Further investigation is required to establish whether the lower affinity of these variants
to plasmin interferes with proper TAFI binding to heparin, and prevents heparin from
eliciting its accelerating function. It will be interesting to find out if combining sets of
mutations, such as R320A/R324A and K327A/R330A is able to yield a variant of TAFI
that is resistant to both heparin-mediated stimulation of activation by plasmin, as well as
stabilization.
Although we identified certain residues that may participate in the binding of
TAFI to heparin, there are still a number of remaining questions. Since both activation of
TAFI and thermal stability of TAFIa will ultimately affect the antifibrinolytic potential of
TAFI, the next step would be to determine the effect of heparin on the antifibrinolytic
effect of TAFI, and to analyze the contribution of the studied residues on the attenuation
of fibrinolysis in the presence and absence of heparin.
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Another issue that still remains unresolved is the contribution of the accelerated
activation of TAFI by plasmin versus the increased stability of TAFI in the presence of
heparin. Mao and coworkers suggested that heparin binding changes TAFI conformation,
making it a better substrate for plasmin activation [43]. However, once activated, TAFI is
extremely unstable. Heparin, however, also stabilizes TAFIa. As a result, heparin
contributes to increased effective TAFIa concentration in both ways. To distinguish
between the two functions of heparin, and to determine the relative contribution of these
functions on the concentration of TAFIa, a stable TAFI variant can be used. Recombinant
TAFI variant, with mutations S305C, and T329I, and an isoleucine at the 325 position,
has a half-life of 70 min [54]. Since this variant is more stable, the increase in TAFIa
activity within a clot will mostly be a result of accelerated activation of TAFI by plasmin.
Alternatively, we could use a mutant such as K327A that is susceptible to heparin
acceleration of activation but not heparin stabilization.
Finally, to understand the full effect of heparin on the TAFI pathway, its
contribution on TAFI activation by thrombin/thrombomodulin complex has to be
investigated. It was reported that presence of heparin actually reduced activation by
thrombin/thrombomodulin complex [44]. However, it is not known whether heparin
binding to TAFI prevents binding of the thrombin/thrombomodulin complex to TAFI, or
if heparin binds directly thrombin/thrombomodulin complex. To investigate that, TAFI
variants that are resistant to heparin binding would have to be used.
Overall, the goal of this study was to identify TAFI residues that participate in
heparin binding, and their contribution on the plasmin-mediated activation and stability of
TAFI. Understanding of the heparin function in respect to TAFI would provide answers
for the overall picture of the role of TAFI in hemostasis of a healthy individual, as well as
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that of an individual that is undergoing anticoagulation with heparin or a related
compound. The anticoagulant properties of heparin may be antagonized by the TAFI
pathway. Understanding the binding sites, and possibly length requirements of heparinlike molecule in respect to TAFI could give rise to a development of a treatment that is
unable to either stabilize TAFI, or accelerate plasmin-mediated activation of TAFI, or
both. Similar approach was taken during the development of the drug Fondaparinux
which exclusively stimulates inhibition of FXa by antithrombin, while having no effect
on inhibition of other proteases of the coagulation pathway. This exclusivity is due to the
fact that a short sequence, present in this heparin-like molecule, is sufficient to stimulate
inhibition of FXa but not other targets, such as thrombin [85]. This potentially could be
the case with plasmin-mediated TAFI activation.
Understanding glycosaminoglycan binding to TAFI is extremely important under
both natural and heparin treatment-induced circumstances. Understanding TAFI
interaction with heparin, heparan sulfate, and other glycosaminoglycans will provide us
with more insight into the contribution of thrombin, the thrombin/thrombomodulin
complex, and plasmin on the localized concentration of TAFIa. In the case of the
anticoagulant treatments with heparin-like drugs, understanding the interaction of heparin
with TAFI and the consequence of this interaction will aid in the development of more
tailored and targeted drugs.
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Appendix
This section summarizes the optimization process for quantification of heparin binding to
TAFI. This section also summarizes the preliminary results for plasmin-mediated
activation and thermal stability of recently developed variants. These variants were
pursued in the later stages of this study and thus complete characterization of these
variants could not be completed. The rationale for the development of variants K59A,
R15A was based on the fact that in a crystal structure of bovine TAFI, a number of
sulfates were bound to charged residues in the pro-domain [1]. Due to the fact that
heparin binding in the pro-domain would not explain the increased stability of TAFI in
the presence of heparin, Anand and coworkers suggested that the pro-domain is not the
most likely heparin binding region. However, binding of heparin to the pro-domain can
have other consequences in respect to TAFI function. Although, the identity of these
residues was not disclosed, using a crystal structure of human TAFI (pdb: 3D66) we
identified residues R15A and K59A to be exposed, and thus they could potentially
facilitate binding to heparin. Another report of a bovine TAFI crustal structure, in the
presence of sulfates, resulted in the development of S316A and S249A/S251A [2].
Preliminary thermal stability experiments were only done on variants S316A and
S249A/S251A since the variants with the mutation in the pro-domain are not likely to
have an effect on the thermal stability in respect to heparin binding.
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A-1 Materials and Methods
Analysis of the dissociation constant between heparin-agarose and TAFI
20µL of Heparin-agarose resin (Sigma-Aldrich) or 4-% agarose resin (MPbiomedicals)
was incubated with increasing concentrations of TAFI (0.02 µM-0.14 µM) for 30 min in
HBS buffer. The mixture was then centrifuged at 3000 rpm, and the supernatant was
removed. The supernatant is thought to contain unbound TAFI. To analyze the
concentration of unbound TAFI versus the concentration of total TAFI, samples were first
subjected to the western blot analysis. Using a standard curve for each experiment, band
analysis was used to quantify the concentration of unbound TAFI, and thus the
concentration of bound TAFI, through subtraction. The values were used to plot total
TAFI concentration, or unbound TAFI concentration versus bound TAFI concentration. A
scatchard plot was also constructed. Due to the scatter in the points, a dissociation
constant could not be obtained. The experiment was repeated a number of times, varying
either the concentrations of TAFI, or the volume of the resin, without an improvement in
the quality of the data. We then investigated whether a different method of TAFI
detection would be more appropriate for this experiment, and thus used enzyme-linked
immunosorbent assay (ELISA). ELISA was carried out as follows. The binding
experiment was performed in the same manner as above, samples representing unbound
TAFI or total TAFI were diluted in coating buffer (0.012M sodium carbonate , 0.028M
sodium bicarbonate pH 9.6) and applied on polystyrene 96-well plates (Corning)
overnight at 4˚C. The wells were washed 3 times with phosphate buffered saline (PBS)
(137 mM NaCl, 1,4 mM KH2PO4, 2.7 mM KCl, 3mM Na2HPO4 pH 7.4) containing
0.1%(v/v)Tween-20.The wells were blocked with blocking solution (PBS containing 3%
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(w/v) bovine serum albumin) for 2 hours at room temperature. The wells were washed
again, and then incubated with 1 μg/mL primary polyclonal sheep anti-TAFI antibody
(Affinity Biologicals) in dilution buffer (HBS containing 1% (w/v) bovine serum
albumin) on a shaker for 1 hour at room temperature.After another wash of the wells, they
were incubated with 1 μg/mL secondary hydrogen peroxide-conjugated anti-sheep IgG
(Thermo Scientific) in the dilution buffer,on a shaker for 1 hour at room temperature. The
wells were then washed again and colour development solution was then applied,
consisting of phenylenediamine dihydrochloride tablet (Sigma-Aldrich) dissolved in a 12
mL of substrate buffer (0.05 M citric acid/sodium-phosphate buffer, pH 5.0); each well
received 100 µL of the solution. Colour development was stopped by the addition of 50
µL of 2M H2SO4 and the absorbance of each well was measured at 490 nm (and corrected
for absorbance at 560 nm) to quantify TAFI present in each well. The total TAFI wells
were used as a standard curve. The dilution of the sample in coating buffer varied
between 2µL-50µL of the sample in total volume of 100µL of coating buffer. The best
standard curve was obtained with the lowest range of 2µL.Calculations of bound and
unbound TAFI were done in the same manner as described above.

A-2 Results
A-2.1 Analysis of the dissociation constant between heparin-agarose and TAFI
Following the elution experiment of TAFI binding to heparin agarose, we set out to
quantify the binding affinity of heparin to TAFI, employing a ligand binding assay. After
varying different aspects of the experimental approach (volume of the resin, concentration
of TAFI, and the detection technique), the dissociation constant could not be determined,
as there was no clear relationship between the increasing concentration of TAFI, and the
87

concentration of bound TAFI. Figure A-1 c) and d) shows that there was no linear
relationship, and the slope, which is used to determine the dissociation constant, could not
be obtained. Due to time constraints, this experiment could not be further optimized, and
it cannot be excluded that the dissociation constant can be quantified with this method.
However, since the number of binding sites and the contribution of these sites to the
binding of heparin to TAFI are unknown, this method may not result in a linear scatchard
plot.
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Figure A-1. Quantitative analysis of the dissociation constant between heparinagarose and TAFI. Panels a) and b) represent the concentration of bound TAFI as a
function of total TAFI for WT and variant R320A/K324A .Panels c) and d) exhibit the
corresponding Scatchard plots of WT and variant R320A/K324A
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A-2.2 Activation of TAFI variants by plasmin in absence and presence of heparin
In respect to TAFI variants R15A, K59A, S316A, and S249A/S251A, preliminary
results show that there is an effect of heparin on plasmin mediated activation of TAFI.
Figure A-2 shows that all of the variants in question displayed increased activation of
TAFI in the presence of heparin. However, whether or not the effect of heparin on
activation of these variants is the same or reduced when compared to wild-type cannot be
concluded using these data, as apparent kcat and Km values cannot be derived with the
same confidence from these single experiments. Due to the nature of the experiment, and
the dependency on the standard curve, the reduced rates of activation for some of these
variants may not be representative of the actual activation kinetics, but rather an artifact
of a single experiment. Therefore, the activation data cannot be compared between
variants.. These data can only be used to suggest that mutation of these residues does not
abolish heparin’s effect on plasmin-mediated activation of TAFI.
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Figure A-2 Plasmin-mediated activation of TAFI variants in presence and absence
of heparin. Variants S249A/S251A(a), S316A(b), K59A(c), and R15A(d) were incubated
with 25 nM plasmin, in the presence (circle) or absence (cross) of 0.02 U/µL heparin for
12 minutes at room temperature. Results are representative of one experiment.
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A-2.3 Thermal stability of TAFI variants in the presence and absence of heparin
Contribution of serine 316, serine 249, and serine 251 on the stability of TAFI in the
presence and absence of heparin was estimated using a thermal stability assay. Figure A-3
and table A-1 display that there is a clear difference in the thermal stability of these
variants in the presence and absence of heparin. From these preliminary results it can be
concluded that mutation of these residues did not abolish the effect of heparin on thermal
stability. However, since these experiments were only done once, it cannot be concluded
if effect of heparin on the stability of these variants is reduced, or the same when
compared to wild-type.
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Figure A-3 Intrinsic stability of TAFIa variants in the absence and presence of
heparin at 37˚C. Variants S316A and S249A were activated in the presence of thrombinTM, and incubated at 37˚C in the presence (circle) or absence (cross) of heparin. TAFIa
activity was measured at different time points. The data were fit to the equation
describing first-order exponential decay in order to determine the half-lives of TAFIa
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Table A-1 Intrinsic stability of TAFIa variants in the absence and presence of
heparin at 37˚C.
Decay constants estimated by the regression of the data in Fig. A-3 were used to calculate
the half-lives of the TAFIa mutant in the absence and presence of heparin.
Variant
S316A
S249A/S251A

Half-life
+ heparin (min)
14.2
11.7

n
-heparin (min)
10.1
7.2
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1
1
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